Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions.
Oncolytic viruses that can destroy cancer cells have been engineered in a variety of ways with the aim of improving their selectivity and efficacy. Here, we review data from clinical investigations of these virotherapeutic agents, specifically those that have shown systemic efficacy: vaccinia, measles, mumps, viruses, Newcastle disease virus, and reovirus. Further directions for optimizing i.v. delivery and efficacy are discussed.
Liu
Ta-Chiang
TC
Brain Tumor Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Kirn
David
D
D002986:Clinical Trials as Topic; D005544:Forecasting; D006801:Humans; D009369:Neoplasms / Q000628:therapy* / Q000821:virology*; D050130:Oncolytic Virotherapy / Q000379:methods*